Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President, Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Andrew Callos - Executive Vice President and Chief Commercial Officer
Stuart Kupfer - Senior Vice President & Chief Medical Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Joe Pantginis - H.C. Wainwright
Jason Zemansky - Bank of America
Carter Gould - Barclays
Tessa Romero - JPMorgan
Dane Leone - Raymond James
Jason Butler - JMP Securities
Charles Duncan - Cantor Fitzgerald
Justin Kim - Oppenheimer
Salim Syed - Mizuho
Serge Belanger - Needham Co
Madhu Kumar - Goldman Sachs
Operator
Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for question-and-answer after the presentation. [Operator Instructions]
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer who will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D will provide updates related to omecamtiv mecarbil and aficamten, as well as other drug candidates comprising our early clinical development pipeline. Andrew Callos, EVP and Chief Commercial Officer will speak further about omecamtiv mecarbil and our specialty cardiology franchise strategy related to aficamten. Stuart Kupfer, SVP and Chief Medical Officer will provide an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer will provide a financial overview of the past quarter and Ching Jaw, SVP and Chief Financial Officer will discuss our 2023 financial guidance and corporate development strategies. Finally, Robert Blum will provide closing comments and review expected key milestones for 2023.
Please note that portions of the following discussion including our responses to questions contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.